Checkpoint@gregoryfca.com
CHECKPOINT THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
March 31, 2024 December 31, 2023
-------------- ---------------------
ASSETS
Current Assets:
Cash and cash equivalents $ 11,241 $ 4,928
Prepaid expenses and
other current assets 734 450
------------- --------------
Total current assets 11,975 5,378
------------- --------------
Total Assets $ 11,975 $ 5,378
============= ==============
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current Liabilities:
Accounts payable and
accrued expenses $ 19,159 $ 15,485
Accounts payable and
accrued expenses -
related party 2,941 2,815
Common stock warrant
liabilities 125 125
------------- --------------
Total current
liabilities 22,225 18,425
------------- --------------
Total Liabilities 22,225 18,425
------------- --------------
Commitments and Contingencies
Stockholders' Equity
(Deficit)
Common Stock ($0.0001 par
value), 80,000,000 shares
authorized as of March 31,
2024 and December 31, 2023
Class A common shares,
700,000 shares issued
and outstanding as of
March 31, 2024 and
December 31, 2023 - -
Common shares, 34,986,279
and 27,042,035 shares
issued and outstanding
as of March 31, 2024 and
December 31, 2023,
respectively 4 3
Common stock issuable,
1,492,915 shares as of March
31, 2024 and December 31,
2023 3,419 3,419
Additional paid-in capital 311,605 297,864
Accumulated deficit (325,278) (314,333)
------------- --------------
Total Stockholders' Equity
(Deficit) (10,250) (13,047)
------------- --------------
Total Liabilities and
Stockholders' Equity
(Deficit) $ 11,975 $ 5,378
============= ==============
CHECKPOINT THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(Unaudited)
For the three months ended March 31,
------------------------------------------
2024 2023
Revenue - related party $ - $ 35
Operating expenses:
Research and
development 8,497 15,826
General and
administrative 2,451 2,292
---------------- ---------------
Total operating expenses 10,948 18,118
---------------- ---------------
Loss from operations (10,948) (18,083)
---------------- ---------------
Other income:
Interest income 4 43
Gain on common stock
warrant
liabilities - 7,566
Foreign currency
exchange loss (1) -
---------------- ---------------
Total other income 3 7,609
---------------- ---------------
Net Loss $ (10,945) $ (10,474)
================ ===============
Loss per Share:
Basic and diluted net
loss per common share
outstanding $ (0.33) $ (0.89)
================ ===============
Basic and diluted
weighted average number
of common shares
outstanding 33,930,977 11,749,139
================ ===============
(END) Dow Jones Newswires
May 10, 2024 08:30 ET (12:30 GMT)
Comments